Scott L Burrows

Chief Financial Officer

Scott L Burrows (Chief Financial Officer) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Spyre Therapeutics, Inc. (SYRE). The largest single filing was $2.2M of SYRE (24,632 sh across 3 lots, as filed), executed Sep 1.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 7 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$6.6M

shares × price, as filed

Last traded

Sep 2

Filed Sep 3

Median ADV $134.1M across their filed names

Open performance→

Volume by month

Buys $0 Sells $6.9M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 7 filings

Sector per market data · by filing · past 12 months

Most traded names

SYRE

Spyre Therapeutics, Inc. SYRE · 0 buys · 8 sells 8 filings

Recent filings

SYRESALE Spyre Therapeutics, Inc. View filing → $2.2M
24,632 sh across 3 lots
Exec Sep 1
Filed Sep 3 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $707K
7,400 sh across 2 lots
Exec Aug 3
Filed Aug 5 · 9:32 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $658K
7,500 sh across 2 lots
Exec Jul 1
Filed Jul 2 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $1.3M
15,000 sh across 2 lots
Exec Jun 25
Filed Jun 26 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $533K
7,500 sh across 3 lots
Exec Jun 1
Filed Jun 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $892K
12,500 sh × $71.37
Exec May 1
Filed May 1 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $305K
6,200 sh × $49.21
Exec Apr 1
Filed Apr 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $300K
18,428 sh × $16.26
Exec Sep 2 2025
Filed Sep 3 2025 · 5:30 PM ET